Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in non-transfusion dependent beta-thalassemia (BEYOND)
NCT03342404Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2018
- Primary completion
- Nov 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of luspatercept in beta thalassemia, sponsored by Celgene Corporation. Started Feb 2018; status: completed.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT03342404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342404.